Dosing and uses of Pro Banthine (propantheline)
Adult dosage forms and strengths
tablet
- 15mg
Peptic Ulcer
15 mg PO q8hr AC & 30 mg PO qHs
Use 7.5 mg PO q8hr for mild conditions
Administration: take 30-60 min before a meaL
Antispasmodic
15 mg PO q8hr AC & 30 mg PO qHs
Other Indications & Uses
PUD (adjunctive treatment)
Off-label: Other conditions requiring antispasmodic and antisecretory agents, neurogenic bladder
Pediatric dosage forms and strengths
tablet
- 15mg
Antisecretory
1-2 mg/kg/day PO q6-8hr
Antispasmodic
2-3 mg/kg/day PO divided q4-6hr & qHs
Peptic Ulcer
Safety & efficacy not established
Administration
Take 30-60 min before a meaL
Geriatric dosage forms and strengths
Avoid except in short-term situations to decrease secretions; high incidence of anticholinergic effects (Beers Criteria)
Peptic Ulcer
Administer 7.5 mg PO q8hr AC and qHS; not to exceed 30 mg q8hr
Antispasmodic
15 mg PO q8hr AC & 30 mg PO qHs
Pro Banthine (propantheline) adverse (side) effects
>10%
Constipation
Dry mouth
Dry skin
Decreased sweating
Frequency not defined
Blurred vision
Sedation
Tachycardia
Dysphagia
Urinary retention
Warnings
Contraindications
Hypersensitivity to propantheline or related compounds
Closed-angle glaucoma, myasthenia gravis, hemorrhage w/ cardiovascular instability, paralytic ileus, intestinal atony of elderly/debilitated pt, obstructive uropathy, toxic megacolon, GI obstruction, tachycardia secondary to cardiac insufficiency or thyrotoxicosis
Cautions
Renal/hepatic/ impairment, BPH, CHF, CAD, HTN, COPD, hiatal hernia, reflux esophagitis, mitral stenosis, brain damage or spastic paralysis in children, salivary secretion d/o, Down synd, autonomic neuropathy, hyperthyroidism, tachyarrythmia, toxin-mediated diarrhea
Elderly (see Beers Criteria)
Risk of heat prostration in high environmental temperature
May affect alertness/ability to perform hazardous tasks
Pregnancy and lactation
Pregnancy category: C
Lactation: not known whether excreted into breast milk
Pregnancy categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.
Pharmacology of Pro Banthine (propantheline)
Mechanism of action
Competitively blocks the action of ACh at postganglionic parasympathetic muscarinic receptor sites
Absorption
Bioavailability: PO <50%, take 30 min before meals
Onset: 30-45 min (PO)
Duration: Upt to 6 hr (PO)
Metabolism
Liver and GI tract
Elimination
Half-life elimination: Biphasic: 57.9 min and 2.93 hr
Total Body Clearance: 79.2 L/hr
Renal Clearance: 11.5 L/hr
Excretion: Urine 6-17.3%, bile, and other body fluid
